Eisai

News

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment availab

News

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

Department of Veterans Affairs will cover the drug for veterans with early-stage Alzheimer's.

News

FDA sets July verdict date for Leqembi, after adcomm meeting

After priority review, regulator will consider upgrading the drug's status to full approval.

News

Leqembi still too pricey, says ICER in updated review

Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.

News

CMS accused of discrimination over Alzheimer’s drug verdict

Decision not to revisit coverage decision for amyloid drugs is slammed by patient groups.

News

Eisai says early Leqembi rollout exceeds its hopes

Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

FDA sets July verdict date for Leqembi, after adcomm meeting

Leqembi still too pricey, says ICER in updated review

CMS accused of discrimination over Alzheimer’s drug verdict

Eisai says early Leqembi rollout exceeds its hopes

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks